Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Servier
Jazz Pharmaceuticals
Novartis
Day One Biopharmaceuticals, Inc.
Oblato, Inc.
Celgene
Istari Oncology, Inc.
Candel Therapeutics, Inc.
OncoSynergy, Inc.
Vanquish Oncology, Inc.
Quadriga Biosciences, Inc.
Biogen
Tocagen Inc.
Tocagen Inc.
Pfizer
Tocagen Inc.
Tocagen Inc.
Tocagen Inc.
Amgen
Exelixis
Angiochem Inc
Novartis
Daiichi Sankyo
INSYS Therapeutics Inc
INSYS Therapeutics Inc
TransMolecular
Pharmacyclics LLC.
MediGene